AI assistant
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2008
Jun 27, 2008
32254_dirs_2008-06-27_1b57cb90-842d-4c04-a2e6-191ea945fcb8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2008-06-19
Reporting Person: Mazzo David J (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 500 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option to purchase CHESS Depositary Interests ("CDI's") | $34.9563 | 2010-09-30 | CDIs (5000) | Direct | |
| Option to purchase CDIs | $5.2245 | 2012-09-30 | CDIs (18750) | Direct |
Footnotes
F1: 6,250 options vest on October 18, 2008, another 6,250 options vest on October 18, 2009, and the final 6,250 options vest on October 18, 2010.
F2: Each CDI represents an interest in one underlying share of common stock of pSivida Corp.
F3: Per CDI. The exercise price was converted from A$0.92 using the noon-day rate of exchange of the Federal Reserve Bank of New York on June 19, 2008, which was US$0.9499 = A$1.00. The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise.
F4: Per CDI. The exercise price was converted from A$0.1375 using the noon-day rate of exchange of the Federal Reserve Bank of New York on June 19, 2008, which was US$0.9499 = A$1.00. The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise.